GE Healthcare Receives Approval for Its Own Manufacturing of Optison

19-11-2013 Business Wire HealthComments (0)

GE HealthcareOptisonPharmaceutical

GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) in-house. Optison is a contrast agent that may improve the visualization of the left ventricular border ─ an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. As a result of the FDA’s action, GE

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top